Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: Case-control study nested within a population based screening programme in Australia

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Crowe, Elizabeth ^a,b   Pandeya, Nirmala ^a   Brotherton, Julia M L ^c   Dobson, Annette J ^a   Kisely, Stephen ^a   Lambert, Stephen B ^a,d   Whiteman, David C ^a,e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b NHS BORDERS   (United Kingdom)

^c VICTORIAN CYTOLOGY SERVICE   (Australia)

^d QUEENSLAND HEALTH   (Australia)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; AUSTRALIA; CANCER PREVENTION; CASE CONTROL STUDY; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOLOGY; FEMALE; FOLLOW UP; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY ANALYSIS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE; VACCINATION;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CERVIX UTERI; CHILD; FEMALE; HUMANS; MASS SCREENING; MASS VACCINATION; PAPILLOMAVIRUS VACCINES; QUEENSLAND; TREATMENT OUTCOME; UTERINE CERVICAL DISEASES; VAGINAL SMEARS; YOUNG ADULT;

EID: 84896499760     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g1458     Document Type: Article

References (24)

1. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43. (Pubitemid 46740303)
2. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
3. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861-8. (Pubitemid 46829356)
4. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70. (Pubitemid 46977438)
5. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow S-N, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14.
6. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Perez G, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009;199:936-44.
7. Bonanni P, Boccalini S, Bechini A. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine 2009;27(Suppl 1):A46-53.
8. Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, et al. Human papillomavirus vaccine introduction-the first five years. Vaccine 2012;30(Suppl 5):F139-48.
9. Gertig DM, Brotherton JML, Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2011;8:171-8.
10. National Cervical Screening Program, Australia. 2013. www.cancerscreening.gov. au/internet/screening/publishing.nsf/Content/NCSP- Policies-1.
11. Queensland Government. The Queensland Cervical Screening Program and Pap Smear Register 10 year report 1999-2009. www.health.qld.gov. au/cervicalscreening/.
12. Queensland Health. The Queensland Cervical Screening Program statistical report 2004-2006. 2012. www.health.qld.gov.au/cervicalscreening/documents/cerv- stat-report0406.pdf.
13. Chief Medical Officer, Department of Health and Ageing, Australian Government. Guidance on revaccination where HPV vaccine doses have been given at less than recommended minimum intervals. 2009. www.health.gov.au/internet/ immunise/publishing.nsf/Content/cmo-full-advice-hpv-cnt/$File/ CMO-full-advice-hpv.pdf.
14. Bender R, Blettner M. Calculating the "number needed to be exposed" with adjustment for confounding variables in epidemiological studies. J Clin Epidemiol 2002;55:525-30. (Pubitemid 34462249)
15. Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007;7:11-22. (Pubitemid 46020844)
16. Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee S-K, Kuypers JM, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-8. (Pubitemid 40271061)
17. Hull BP, Lawrence GL, MacIntyre CR, McIntyre PB. Estimating immunisation coverage: is the 'third dose assumption' still valid? Commun Dis Intell 2003;27:357-61.
18. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32. (Pubitemid 46986496)
19. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013;11:227.
20. Muñoz N, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010;102:325-39.
21. Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012;344:e1401.
22. Nitsch D, Morton S, De Stavola BL, Clark H, Leon DA. How good is probabilistic record linkage to reconstruct reproductive histories? Results from the Aberdeen children of the 1950s study. BMC Med Res Methodol 2006;6:15.
23. Castle PE, Schmeler KM. Optimizing cervical cancer prevention strategies in the United States. Gynecol Oncol 2012;127:437-9.
24. Australian Government Department of Health. National Cervical Screening Program Renewal. 2013. www.cancerscreening.gov. au/internet/screening/ publishing.nsf/Content/ncsp-renewal.